SWS Medical(SH:688410) Shang Hai Zheng Quan Bao·2025-09-11 19:10Core Viewpoint - The announcement details the share reduction plans of major shareholders and executives of Chongqing Shanwaishan Blood Purification Technology Co., Ltd, indicating a significant potential decrease in shareholding by key stakeholders due to personal financial needs [3][4]. Shareholding Overview - As of the announcement date, major shareholders Hunan Xiangjiang Liyuan Investment Management Co., Ltd and its action-in-concert partner hold a combined total of 28,849,759 shares, representing approximately 8.98% of the company's total equity [2]. - The company's director and core technical personnel, Ren Yingxiang, holds 998,157 shares, accounting for about 0.31% of the total equity [2]. Reduction Plans - Major shareholder Hunan Xiangjiang Liyuan plans to reduce its holdings by up to 12,852,625 shares, not exceeding 4.00% of the total equity, within a specified period from October 14, 2025, to January 11, 2026 [3]. - Ren Yingxiang intends to reduce his holdings by up to 249,539 shares, not exceeding 0.08% of the total equity, during the same period [4]. Compliance and Commitments - The major shareholder has committed to comply with relevant regulations regarding share reduction, including adhering to the rules set by the China Securities Regulatory Commission and the Shanghai Stock Exchange [6][10]. - Ren Yingxiang has made commitments regarding the timing and pricing of his share reductions, ensuring that the price will not be lower than the adjusted issue price during the specified period [4][8]. Additional Information - The reduction plans are subject to adjustments based on any changes in the company's total equity due to corporate actions such as stock splits or new share issuances [3][4]. - The announcement confirms that the reduction plans align with previously disclosed commitments and do not involve any shares from unprofitable companies [7][10].